Results 231 to 240 of about 536,441 (334)

Aurora A binds to the transactivation domain of c-Myc and recognizes the phosphorylated N-terminal degron motif. [PDF]

open access: yesBiochem J
Joshi N   +7 more
europepmc   +1 more source

High prevalence of patent foramen ovale in migraine with aura [PDF]

open access: hybrid, 2005
G. Ferrarini   +5 more
openalex   +1 more source

A Scalable L‐α‐Glycerophosphorylcholine Synthesis through the Automatic pH‐Controlled (R)‐Glycidol Ring Opening with Phosphorylcholine

open access: yesChemistry–Methods, EarlyView.
Automatic titrator enables the regioselective ring opening of (R)‐glycidol in water in the presence of phosphorylcholine, leading to the synthesis of L‐α‐glycerophosphorylcholine, a commercially available drug, in very high yield. The reaction is triggered by a minimum amount of NaOH and reactants, while the optimal pH is precisely regulated through ...
Antonio Massa   +2 more
wiley   +1 more source

Unveiling the Materiality of 19th Century's Color Spaces

open access: yesColor Research &Application, EarlyView.
ABSTRACT Several color theories flourished during the 19th century, marked by experiments on the distinction between color‐light and color‐matter. This study aims to compare the color plates designed to illustrate three of these color theories, namely M.E. Chevreul's chromatic circle (1861), O. Rood's frontispiece (1879), and C.
Aurore Malmert   +3 more
wiley   +1 more source

Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR‐Mutated Advanced NSCLC

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Osimertinib, a third‐generation, central nervous system‐active epidermal growth factor receptor‐tyrosine kinase inhibitor, potently and selectively inhibits epidermal growth factor receptor‐tyrosine kinase inhibitor sensitizing and T790M resistance mutations, with efficacy in epidermal growth factor receptor‐mutated non‐small cell lung cancer.
Jincheng Yang   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy